What question did this study set out to answer?

To address preexisting immunogenicity that interferes with the performance of ADA assays for ALXN-X.

February 5, 2026

Mitigation of pre-existing immunogenicity in ADA method development

Key Points

To address preexisting immunogenicity that interferes with the performance of ADA assays for ALXN-X.
Developed a modified ADA assay to reduce interference from immunoglobulin-mediated reactivity.
Tested the ability of the modified assay to detect ALXN-X-specific ADA.
The modified assay significantly mitigated the interference from preexisting immunogenicity.
Detection of ALXN-X-specific ADA was preserved, enhancing the reliability of immunogenicity assessments.

Abstract

Preexisting, immunoglobulin-mediated reactivity targeting ALXN-X's Cterminal framework sequence complicates ADA assay performance. A modified ADA assay mitigates this interference while preserving detection of ALXN-X-specific ADA, supporting more reliable immunogenicity assessment.

Ask AI

Helpful

Bookmark